Other genes mutated both in CLPD-NK and ANKL patients included DDX11, RSF1, and KRAS. Tyrosine phosphatase mutations were reported in ANKL and are considered a hallmark of NKTCL, whereas in our CLPD-NK cohort only one tyrosine phosphatase (PTPRN) was mutated. The gene discussed is KRAS; the disease is aggressive NK-cell leukemia.